Cullinan Therapeutics (CGEM) Receives EMA Approval for Rheumatoid Arthritis Trial

Cullinan Therapeutics receives EMA approval for rheumatoid arthritis drug trial

The EMA has approved Cullinan Therapeutics’ clinical trial application for CLN-978, a drug intended to treat rheumatoid arthritis.The post Cullinan Therapeutics receives EMA approval for rheumatoid arthritis drug trial appeared first on Clinical Trials Arena.

Cullinan Therapeutics (CGEM) Receives EMA Approval for Rheumatoid Arthritis Trial

Cullinan Therapeutics (CGEM, Financial) has secured approval from the European Medicines Agency for its Clinical Trial Application concerning CLN-978. This green light allows the company to proceed with a Phase 1 clinical trial aimed at evaluating the treatment in patients suffering from active, challenging cases of rheumatoid arthritis that align with the 2010 classification standards set by the American College of Rheumatology and the European…